Cargando…
LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036232/ https://www.ncbi.nlm.nih.gov/pubmed/26206664 http://dx.doi.org/10.1136/gutjnl-2014-308810 |
_version_ | 1782455523576119296 |
---|---|
author | Scarzello, Anthony J Jiang, Qun Back, Timothy Dang, Hien Hodge, Deborah Hanson, Charlotte Subleski, Jeffrey Weiss, Jonathan M Stauffer, Jimmy K Chaisaingmongkol, Jitti Rabibhadana, Siritida Ruchirawat, Mathuros Ortaldo, John Wang, Xin Wei Norris, Paula S Ware, Carl F Wiltrout, Robert H |
author_facet | Scarzello, Anthony J Jiang, Qun Back, Timothy Dang, Hien Hodge, Deborah Hanson, Charlotte Subleski, Jeffrey Weiss, Jonathan M Stauffer, Jimmy K Chaisaingmongkol, Jitti Rabibhadana, Siritida Ruchirawat, Mathuros Ortaldo, John Wang, Xin Wei Norris, Paula S Ware, Carl F Wiltrout, Robert H |
author_sort | Scarzello, Anthony J |
collection | PubMed |
description | OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the interdependence of inflammatory lymphotoxin signalling and specific oncogenic pathways in the progression of hepatic cancer. DESIGN: Pathologically distinct liver tumours were initiated by hydrodynamic transfection of oncogenic V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT)/β-catenin or AKT/Notch expressing plasmids. To investigate the relationship of LTβR signalling and specific oncogenic pathways, LTβR antagonist (LTβR-Fc) or agonist (anti-LTβR) were administered post oncogene transfection. Initiated livers/tumours were investigated for changes in oncogene expression, tumour proliferation, progression, latency and pathology. Moreover, specific LTβR-mediated molecular events were investigated in human liver cancer cell lines and through transcriptional analyses of samples from patients with intrahepatic cholangiocarcinoma (ICC). RESULTS: AKT/β-catenin-transfected livers displayed increased expression of LTβ and LTβR, with antagonism of LTβR signalling reducing tumour progression and enhancing survival. Conversely, enforced LTβR-activation of AKT/β-catenin-initiated tumours induced robust increases in proliferation and progression of hepatic tumour phenotypes in an AKT-dependent manner. LTβR-activation also rapidly accelerated ICC progression initiated by AKT/Notch, but not Notch alone. Moreover, LTβR-accelerated development coincides with increases of Notch, Hes1, c-MYC, pAKT and β-catenin. We further demonstrate LTβR signalling in human liver cancer cell lines to be a regulator of Notch, pAKT(ser473) and β-catenin. Transcriptome analysis of samples from patients with ICC links increased LTβR network expression with poor patient survival, increased Notch1 expression and Notch and AKT/PI3K signalling. CONCLUSIONS: Our findings link LTβR and oncogenic AKT signalling in the development of ICC. |
format | Online Article Text |
id | pubmed-5036232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50362322016-10-17 LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours Scarzello, Anthony J Jiang, Qun Back, Timothy Dang, Hien Hodge, Deborah Hanson, Charlotte Subleski, Jeffrey Weiss, Jonathan M Stauffer, Jimmy K Chaisaingmongkol, Jitti Rabibhadana, Siritida Ruchirawat, Mathuros Ortaldo, John Wang, Xin Wei Norris, Paula S Ware, Carl F Wiltrout, Robert H Gut Hepatology OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the interdependence of inflammatory lymphotoxin signalling and specific oncogenic pathways in the progression of hepatic cancer. DESIGN: Pathologically distinct liver tumours were initiated by hydrodynamic transfection of oncogenic V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT)/β-catenin or AKT/Notch expressing plasmids. To investigate the relationship of LTβR signalling and specific oncogenic pathways, LTβR antagonist (LTβR-Fc) or agonist (anti-LTβR) were administered post oncogene transfection. Initiated livers/tumours were investigated for changes in oncogene expression, tumour proliferation, progression, latency and pathology. Moreover, specific LTβR-mediated molecular events were investigated in human liver cancer cell lines and through transcriptional analyses of samples from patients with intrahepatic cholangiocarcinoma (ICC). RESULTS: AKT/β-catenin-transfected livers displayed increased expression of LTβ and LTβR, with antagonism of LTβR signalling reducing tumour progression and enhancing survival. Conversely, enforced LTβR-activation of AKT/β-catenin-initiated tumours induced robust increases in proliferation and progression of hepatic tumour phenotypes in an AKT-dependent manner. LTβR-activation also rapidly accelerated ICC progression initiated by AKT/Notch, but not Notch alone. Moreover, LTβR-accelerated development coincides with increases of Notch, Hes1, c-MYC, pAKT and β-catenin. We further demonstrate LTβR signalling in human liver cancer cell lines to be a regulator of Notch, pAKT(ser473) and β-catenin. Transcriptome analysis of samples from patients with ICC links increased LTβR network expression with poor patient survival, increased Notch1 expression and Notch and AKT/PI3K signalling. CONCLUSIONS: Our findings link LTβR and oncogenic AKT signalling in the development of ICC. BMJ Publishing Group 2016-10 2015-07-23 /pmc/articles/PMC5036232/ /pubmed/26206664 http://dx.doi.org/10.1136/gutjnl-2014-308810 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Hepatology Scarzello, Anthony J Jiang, Qun Back, Timothy Dang, Hien Hodge, Deborah Hanson, Charlotte Subleski, Jeffrey Weiss, Jonathan M Stauffer, Jimmy K Chaisaingmongkol, Jitti Rabibhadana, Siritida Ruchirawat, Mathuros Ortaldo, John Wang, Xin Wei Norris, Paula S Ware, Carl F Wiltrout, Robert H LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title_full | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title_fullStr | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title_full_unstemmed | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title_short | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
title_sort | ltβr signalling preferentially accelerates oncogenic akt-initiated liver tumours |
topic | Hepatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036232/ https://www.ncbi.nlm.nih.gov/pubmed/26206664 http://dx.doi.org/10.1136/gutjnl-2014-308810 |
work_keys_str_mv | AT scarzelloanthonyj ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT jiangqun ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT backtimothy ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT danghien ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT hodgedeborah ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT hansoncharlotte ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT subleskijeffrey ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT weissjonathanm ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT staufferjimmyk ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT chaisaingmongkoljitti ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT rabibhadanasiritida ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT ruchirawatmathuros ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT ortaldojohn ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT wangxinwei ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT norrispaulas ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT warecarlf ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours AT wiltroutroberth ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours |